Squarepoint
ABOS icon

Squarepoint’s Acumen Pharmaceuticals ABOS Stock Holding History

Squarepoint’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.4K Buy
+15,015
New +$38.3K ﹤0.01% 4159
2025
Q2 		– Sell
-11,189
Closed -$12.3K – 4420
2025
Q1 		$12.3K Sell
11,189
-626
-5% -$894 ﹤0.01% 4457
2024
Q4 		$20.3K Buy
+11,815
New +$28.4K ﹤0.01% 4935
2024
Q2 		– Sell
-113,232
Closed -$459K – 3983
2024
Q1 		$459K Buy
113,232
+60,403
+114% +$228K ﹤0.01% 3105
2023
Q4 		$203K Buy
+52,829
New +$157K ﹤0.01% 3589
2023
Q3 		– Sell
-10,445
Closed -$50.2K – 3723
2023
Q2 		$50.2K Sell
10,445
-8,898
-46% -$42.6K ﹤0.01% 3439
2023
Q1 		$78.5K Buy
+19,343
New +$101K ﹤0.01% 3015
2022
Q1 		– Sell
-18,818
Closed -$127K – 2741
2021
Q4 		$127K Buy
+18,818
New +$207K ﹤0.01% 2860

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Squarepoint's ABOS Position: Q1 2026 in Review

Squarepoint opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 15,015 shares worth $35.4K. The stake represents ﹤0.01% of the portfolio and ranks #4159 among its holdings. This is a return to the name: Squarepoint previously reported a position in ABOS as recently as Q1 2025.

Squarepoint first reported a position in ABOS in Q4 2021 and has held it in 8 quarters since. The position peaked at $459K in Q1 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Squarepoint held 15,015 shares of Acumen Pharmaceuticals worth $35.4K as of Q1 2026.
  • Acumen Pharmaceuticals was a new Squarepoint position in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4159 holding.
  • Squarepoint first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
  • Squarepoint's Acumen Pharmaceuticals position peaked at $459K in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.